109 related articles for article (PubMed ID: 32514046)
1. DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer.
Sigin VO; Kalinkin AI; Kuznetsova EB; Simonova OA; Chesnokova GG; Litviakov NV; Slonimskaya EM; Tsyganov MM; Ibragimova MK; Volodin IV; Vinogradov II; Vinogradov MI; Vinogradov IY; Kutsev SI; Strelnikov VV; Zaletaev DV; Tanas AS
Sci Rep; 2020 Jun; 10(1):9239. PubMed ID: 32514046
[TBL] [Abstract][Full Text] [Related]
2. DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer.
Sigin VO; Kalinkin AI; Nikolaeva AF; Ignatova EO; Kuznetsova EB; Chesnokova GG; Litviakov NV; Tsyganov MM; Ibragimova MK; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900421
[TBL] [Abstract][Full Text] [Related]
3. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
4. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
[TBL] [Abstract][Full Text] [Related]
5. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
[TBL] [Abstract][Full Text] [Related]
7. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
8. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
10. Comparison of strain and shear-wave ultrasounic elastography in predicting the pathological response to neoadjuvant chemotherapy in breast cancers.
Ma Y; Zhang S; Li J; Li J; Kang Y; Ren W
Eur Radiol; 2017 Jun; 27(6):2282-2291. PubMed ID: 27752835
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?
Maier AM; Heil J; Harcos A; Sinn HP; Rauch G; Uhlmann L; Gomez C; Stieber A; Funk A; Barr RG; Hennigs A; Riedel F; Schäfgen B; Hug S; Marmé F; Sohn C; Golatta M
Eur J Radiol; 2020 Jul; 128():109025. PubMed ID: 32371182
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
14. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
[TBL] [Abstract][Full Text] [Related]
15. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
[TBL] [Abstract][Full Text] [Related]
16. Individual and joint performance of DNA methylation profiles, genetic risk score and environmental risk scores for predicting breast cancer risk.
Guan Z; Raut JR; Weigl K; Schöttker B; Holleczek B; Zhang Y; Brenner H
Mol Oncol; 2020 Jan; 14(1):42-53. PubMed ID: 31677238
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
[TBL] [Abstract][Full Text] [Related]
19. [Association between AOX1, IRF4 methylation in peripheral blood leukocyte DNA and the risks of breast cancer: a case-control study].
Zhang H; Liu YP; Ge AQ; Wang X; Sun HR; Bi HR; Pang D; Zhao YS
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Sep; 39(9):1265-1269. PubMed ID: 30293322
[No Abstract] [Full Text] [Related]
20. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
